Literature DB >> 10208277

Xanthogranuloma of the sellar region: a clinicopathological entity different from adamantinomatous craniopharyngioma.

W Paulus1, J Honegger, K Keyvani, R Fahlbusch.   

Abstract

Xanthogranulomatous change of craniopharyngioma, consisting of cholesterol clefts, macrophages, chronic inflammatory infiltrates, necrotic debris and hemosiderin deposits, has been traditionally considered a hallmark of the adamantinomatous variant, even in the absence of epithelium. Based on a series of 110 craniopharyngioma patients undergoing primary surgery, we found 37 specimens with a predominating xanthogranulomatous component. Only 3 of these cases (8%) exhibited additional histological features of adamantinomatous craniopharyngioma, while 13 cases (35%) contained non-adamantinomatous epithelium composed of squamous or ciliated cuboidal cells. Subsequent clinical analysis revealed that these 37 xanthogranulomatous lesions differed from 59 classical adamantinomatous craniopharyngiomas with respect to preferential occurrence in adolescents and young adults (mean age 27 years), predominant intrasellar location, smaller tumor size, more severe endocrinological deficits, longer preoperative history, lower frequency of calcification and visual disturbances, better resectability, and a more favorable outcome. On the other hand, xanthogranulomatous and adamantinomatous lesions did not differ with respect to sex, amount of cystic components, or the intraoperative aspect, considered by the neurosurgeon as being typical for craniopharyngioma in all cases. We suggest that xanthogranuloma (cholesterol granuloma) of the sellar region is clinically and pathologically distinct from the classical adamantinomatous craniopharyngioma.

Entities:  

Mesh:

Year:  1999        PMID: 10208277     DOI: 10.1007/s004010051001

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  28 in total

1.  [The 2017 WHO classification of pituitary tumors].

Authors:  Wolfgang Saeger
Journal:  Pathologe       Date:  2021-04-20       Impact factor: 1.011

Review 2.  [New aspects of tumor pathology of the pituitary].

Authors:  W Saeger
Journal:  Pathologe       Date:  2015-05       Impact factor: 1.011

Review 3.  [Hypophysitis : Types and differential diagnosis].

Authors:  W Saeger
Journal:  Pathologe       Date:  2016-05       Impact factor: 1.011

4.  Endocrinological and MRI features of pituitary adenomas with marked xanthogranulomatous reaction.

Authors:  Hiroshi Nishioka; Makoto Shibuya; Kuninori Ohtsuka; Yukio Ikeda; Jo Haraoka
Journal:  Neuroradiology       Date:  2010-03-18       Impact factor: 2.804

Review 5.  Cholesterol granulomas presenting as sellar masses: a similar, but clinically distinct entity from craniopharyngioma and Rathke's cleft cyst.

Authors:  Raúl A Hernández-Estrada; Varun R Kshettry; Ashley N Vogel; Mark T Curtis; James J Evans
Journal:  Pituitary       Date:  2017-06       Impact factor: 4.107

Review 6.  Xanthomatous pituitary lesions: a report of two cases and review of the literature.

Authors:  Morton G Burt; Adrienne L Morey; Jenny J Turner; Malcolm Pell; John P Sheehy; Ken K Y Ho
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

Review 7.  Neuroradiologic review in pediatric brain tumor studies.

Authors:  Monika Warmuth-Metz; Brigitte Bison; Susanne Leykamm
Journal:  Klin Neuroradiol       Date:  2009-11-21

8.  Xanthogranulomatous pituitary adenoma: A case report and literature review.

Authors:  Guihong Li; Chaochao Zhang; Yuxue Sun; Qingchun Mu; Haiyan Huang
Journal:  Mol Clin Oncol       Date:  2018-01-10

9.  Pituitary adenoma with tumoral granulomatous reaction.

Authors:  Bernd W Scheithauer; Ana Isabel Silva; John L D Atkinson; Todd B Nippoldt; Timothy J Kaufmann; Kalman Kovacs; Eva Horvath; Ricardo Lloyd
Journal:  Endocr Pathol       Date:  2007       Impact factor: 3.943

10.  Comparative immunohistochemical assessment of craniopharyngioma and related lesions.

Authors:  Brian H Le; Javad Towfighi; Silloo B Kapadia; M Beatriz S Lopes
Journal:  Endocr Pathol       Date:  2007       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.